stockrow
Friday 6 November 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
31.60
2.02
+6.83%
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) Debt to equity
Cogent Biosciences, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 0.4×, up 0.1× from fiscal 2025 (0.4×). Over the past ten years it has ranged from 0.0× (fiscal 2024) to 0.4× (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.4× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.1× | 1,728.21% |
| FY2021 | 0.0× | (70.90%) |
| FY2020 | 0.0× | (90.35%) |
| FY2019 | 0.1× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 0.4× | 14.30% |
| Mar 2026 | 0.4× | 4.82% |
| Dec 2025 | 0.4× | 139.44% |
| Sep 2025 | 0.1× | — |
| 36 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.4×
Ten-year median
0.0×
Current reading's percentile
100
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | −14.9× |
| ERAS Erasca, Inc. compare | 0.0× |
| DNTH Dianthus Therapeutics, Inc. compare | 0.0× |
| MANE Veradermics Incorporated compare | 0.0× |
| KOD Kodiak Sciences Inc. compare | 0.0× |
| CRSP CRISPR Therapeutics AG compare | 0.4× |
| COGT Cogent Biosciences, Inc. | 0.4× |
| SRRK Scholar Rock Holding Corporation compare | 0.8× |
| TVTX Travere Therapeutics, Inc. compare | 26.7× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement